LASIK for Myopia and Astigmatism Using the SCHWIND AMARIS Excimer Laser: An International Multicenter Trial

Abstract

Treatment of myopia with astigmatism using the SCHWIND AMARIS excimer laser is safe, efficacious, predictable, and maintains visual quality.

Results of laser in situ keratomileusis performed using solid-state laser technology

“…12 In our study, the overall mean efficacy index was 0.99 and safety index, 1.02. These values are comparable to those obtained after myopic LASIK with the last generation of excimer lasers [16][17][18][19][20] (Table 2). Comparisons of the data in Table 2 should be performed with caution because the data represent different samples of eyes operated on by different physicians using different technologies.…”

“…Similarly, in the study by Tsiklis et al 10 of myopic eyes that had LASIK with the same technology, 90% of eyes had an SE within G0.50 D ( Table 2). This level of refractive correction predictability is equivalent to, and in some cases better than, that reported with the last generation of excimer lasers (SE within G0.50 D in 90% of eyes or more) 10,[16][17][18][19][20] (Table 2). This excellent refractive predictability was confirmed with the defocus equivalent analysis, which was significantly reduced postoperatively (0.50 D or less in 93.3% of eyes).…”

Laser in situ keratomileusis using optimized aspheric profiles and cyclotorsion control to treat compound myopic astigmatism with high cylinder

“…However, the recent evolution in excimer laser technology had led to substantial improvements in astigmatic corrections. The aim of this study was to determine the applicability of the improved, new-generation laser platform with an optimized aspheric ablation profile, cyclotorsion control, improved centration, and a fast repetition rate for the treatment of compound myopic astigmatism with cylinder O3.00 D. Few studies [16][17][18] report the results of LASIK to correct myopic astigmatism with high cylinder. This could be because high-cylinder myopic compound astigmatism is not a frequent refractive problem in the normal population.…”

Meta-analysis of Six Excimer Laser Platforms for Safety and Efficacy in Myopic Laser-assisted in situ Keratomileusis

“…Abbott excimer platform-20/20-88 % 8 Alcon excimer platform-20/12.5-25 %, 35 20/16-62 %, 9 20/20-92 % 9 Carl Zeiss excimer platform-20/20-93 % 37 Nidek excimer platform-20/12.5-15 %, 21 20/16-85 %, 21 20/20-97 % 21 Schwind excimer platform-20/12.5-3 %, 28 20/16-65 %, 26 20/20-98 % 26 Technolas excimer platform-20/12.5-2 %, 31 20/16-70 %, 36 20/20-87 % 33 (see Figure 3) The Nidek platform was significantly superior to all the other platforms at acuity level 20/16 (see Table 3). Technolas excimer platform-20/16-65 %, 32 20/20-81 % 32 (see Figure 4).…”

“…Carl Zeiss excimer platform-3 month-94 %, 14 6 month-98 %, 17 12 month-98 % 19 Nidek excimer platform-3 month-91 %, 22 6 month-89 %, 21 12 month-85 % 20 Schwind excimer platform-3 month-96 %, 28 6 month-96 %, 26 12 month-95 % 29 Technolas excimer platform-3 month-98 %, 11 6 month-94 %, 31 12 month-86 % 32 (see Figure 5) The Carl Zeiss platform was superior to all the other platforms at 6 months (see Table 5)…”